Skip to main content
SpringerLink
Log in

What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?

  • Practice Point
  • Published:

From Nature Clinical Practice Gastroenterology & Hepatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sutherland L et al. (2002) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 4: CD000544

    Google Scholar 

  2. Bebb JR and Scott BB (2004) Systematic review: how effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 20: 143–149

    Article  CAS  Google Scholar 

  3. Hanauer SB et al. (2005) Efficacy and safety of mesalazine 4.8 g/day (800 mg tablet) compared with 2.4 g/day (400 mg tablet) in treating moderately active ulcerative colitis: ASCEND II study [abstract]. Gut 53 (Suppl 2): A3

    Google Scholar 

  4. Travis SPL et al. (1994) The optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 35: 1282–1286

    Article  CAS  Google Scholar 

  5. Frieri G et al. (2005) Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis 37: 92–96

    Article  CAS  Google Scholar 

  6. Kane S et al. (2003) Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114: 39–43

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Katy Cherry, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Consultant Gastroenterologist and Clinical Director of the Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK

    Simon Travis

Authors
  1. Simon Travis
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author is in receipt of unrestricted educational grants, or consultancy fees or lecturing fees from Celltech, Ferring Pharmaceuticals, Proctor and Gamble, and Shire Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Travis, S. What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?. Nat Rev Gastroenterol Hepatol 2, 564–565 (2005). https://doi.org/10.1038/ncpgasthep0336

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0336

  • Springer Nature Limited

This article is cited by

Search

Navigation